While biomarkers such as brachyury, a transcription factor that is important for chordoma progression, have been robustly investigated and now have associated immunotherapeutic agents being tested in trials, other biomarkers such as CSPG4 require additional research to elucidate potential clinical relevance. The gene discussed is TBX1; the disease is chordoma.